Venlafaxine

The outcome is relapse, and in the underlying trials relapse was not reliably told apart from withdrawal. Slow means longer than four weeks, not the months-long schedules now advised. Venlafaxine was not separated from other antidepressants. The therapy comparison rests on two studies.

Trials of tapering exist for antidepressants as a class, so venlafaxine's share of that evidence is real but unlabelled. The registry count is from ClinicalTrials.gov alone. The guideline review closed in May 2021, before the UK guideline of 2022 added its schedule; the label's schedule is the one its trials happened to use.

A report count is not a rate: it says withdrawal made up a large share of a drug's reports, not how many users had it. The drugs with the strongest signals were also the most reported and most talked about, which the authors say may inflate their ratios. Among 19 people who had once stopped fluoxetine, a drug that lingers for weeks, remembered withdrawal was as severe as after venlafaxine.

One trial of 103 people, with venlafaxine pooled among drugs of its class and prediction intervals wide enough that the 29% could be anywhere from 8% to 72%. Taper lengths were chosen by the clinic. Whether withdrawal causes relapse or the two share a cause is not settled by this design.

Twenty-three of the 61 reports were single case reports, and no pooled figure exists for how many people get a prolonged course. The label's drawn-out cases come from voluntary reports with no denominator. NICE puts the usual course at one to two weeks, occasionally months.

Every one of these measured what people said or reported, not a biological marker, so the pattern could reflect reporting as much as experience. The reporting-database figure has no denominator of users. None separates venlafaxine from other antidepressants.

The argument comes from imaging of SSRIs, not venlafaxine, and from receptor occupancy rather than from a trial that measured how people felt. No randomised trial has compared hyperbolic with straight-line tapering of venlafaxine.

Nobody tapered without the strips for comparison, so the figures describe the users, not the strips' effect. Response rates were 48% and 59%, and outcomes were self-reported, some recalled from up to five years earlier. The authors' institute received a grant from the pharmacy that makes the strips.

The three dose figures are second-hand: a 2022 review copied them from a 2005 UK regulator's report, and the report itself is where the counts live. The middle dose came out lower than the lowest, so the rise rests on the 150 mg group alone. The label gives the trend and no number.

The survey reached 18% of those invited, all recalling past attempts, which plausibly inflates every figure, and it did not separate venlafaxine from other antidepressants. The tenfold odds ratio ran from about 3 to 38. The label states the trend without a number. The tapering cohort had no comparison group.

Whether years on venlafaxine make it harder to stop is open. The label and long-term users say yes; the trials that say no lasted only weeks, so they never tested the question.

The percentages were extracted by a later review from the trial's tables; the trial's own summary gives only the direction. Withdrawal was a side outcome of a trial built to compare how well the drugs worked, after eight weeks of use, so it says nothing about longer use. A review of 61 reports found withdrawal most often with venlafaxine but could give no pooled figure.

The trial's taper lengths were chosen by the clinic, not randomised, and ran weeks. The cohort had no group tapering without the strips, and the 608 who rated symptoms daily were a self-selected minority of 3,956 users, most of whom had failed before. The cohort's authors developed the strips.

Whether a slower venlafaxine taper spares withdrawal is unsettled. A cohort that chose slow tapering says yes, a trial with few-week tapers says no, and neither tested the months-long schedule now recommended.